Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic and Predictive Ability of Tumor Sidedness

Prognostic and Predictive Ability of Tumor Sidedness Opinion Editorial 5. Hahnen E, Lederer B, Hauke J, et al. Germline 9. Sikov WM, Berry DA, Perou CM, et al. Event-free early-stage breast cancer: a multicentric analysis of mutation status, pathological complete response, and overall survival following neoadjuvant weekly rates of pathologic complete response and survival. and disease-free survival in triple-negative breast paclitaxel and dose-dense AC +/− carboplatin J Chemother. 2016;28(3):210-217. cancer: secondary analysis of the GeparSixto and/or bevacizumab in triple-negative breast 14. Sharma P, López-Tarruella S, García-Saenz JA, randomized clinical trial [published online July 13, cancer: outcomes from CALGB 40603 (Alliance). et al. Efficacy of neoadjuvant carboplatin plus 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.1007 Paper presented at: San Antonio Breast Cancer docetaxel in triple-negative breast cancer: Symposium; December 9, 2015, San Antonio, TX. 6. von Minckwitz G, Schneeweiss A, Loibl S, et al. combined analysis of two cohorts. Clin Cancer Res. Neoadjuvant carboplatin in patients with 10. Arun B, Bayraktar S, Liu DD, et al. Response to 2017;23(3):649-657. triple-negative and HER2-positive early breast neoadjuvant systemic therapy for breast cancer in 15. Gluz O, Nitz U, Liedtke C, et al. Comparison of cancer (GeparSixto; GBG 66): a randomised phase 2 BRCA mutation carriers and noncarriers: 12 weeks neoadjuvant nab-paclitaxel combined http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Prognostic and Predictive Ability of Tumor Sidedness

Chang, George J.; Gonen, Mithat
JAMA Oncology , Volume 3 (10) – Oct 8, 2017
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/prognostic-and-predictive-ability-of-tumor-sidedness-hb2B3XjelL

References (8)

  • Michael Lee, D. Menter, S. Kopetz (2017)

    Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.

    Journal of the National Comprehensive Cancer Network : JNCCN, 15 3

  • S. Tejpar, S. Stintzing, F. Ciardiello, J. Tabernero, E. Cutsem, F. Beier, R. Esser, H. Lenz, V. Heinemann (2017)

    Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

    JAMA Oncology, 3

  • F. Sinicrope, Q. Shi, C. Allegra, T. Smyrk, S. Thibodeau, R. Goldberg, J. Meyers, K. Pogue-Geile, G. Yothers, D. Sargent, S. Alberts (2017)

    Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials

    JAMA Oncology, 3

  • F. Petrelli, G. Tomasello, K. Borgonovo, M. Ghidini, L. Turati, P. Dallera, R. Passalacqua, G. Sgroi, S. Barni (2017)

    Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis

    JAMA Oncology, 3

  • S. Karim, K. Brennan, S. Nanji, S. Berry, C. Booth (2017)

    Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer

    JAMA Oncology, 3

  • D. Muzny, M. Bainbridge, K. Chang, H. Dinh, J. Drummond, G. Fowler, C. Kovar, L. Lewis, M. Morgan, I. Newsham, J. Reid, J. Santibanez, E. Shinbrot, L. Treviño, Yuan-qing Wu, Min Wang, P. Gunaratne, L. Donehower, C. Creighton, D. Wheeler, R. Gibbs, M. Lawrence, Douglas Voet, R. Jing, K. Cibulskis, A. Sivachenko, P. Stojanov, A. McKenna, E. Lander, S. Gabriel, L. Ding, R. Fulton, D. Koboldt, T. Wylie, Jason Walker, D. Dooling, L. Fulton, K. Delehaunty, C. Fronick, Ryan Demeter, E. Mardis, R. Wilson, Andy Chu, Hye-Jung Chun, A. Mungall, E. Pleasance, A. Robertson, D. Stoll, M. Balasundaram, I. Birol, Y. Butterfield, E. Chuah, R. Coope, Noreen Dhalla, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Darlene Lee, H. Li, Michael Mayo, Richard Moore, J. Schein, Jared Slobodan, Angela Tam, N. Thiessen, R. Varhol, Thomas Zeng, Yongjun Zhao, Steven Jones, M. Marra, A. Bass, A. Ramos, G. Saksena, A. Cherniack, S. Schumacher, B. Tabak, S. Carter, Nam Pho, Huy Nguyen, R. Onofrio, A. Crenshaw, K. Ardlie, R. Beroukhim, W. Winckler, M. Meyerson, A. Protopopov, Angela Hadjipanayis, E. Lee, Ruibin Xi, Lixing Yang, X. Ren, N. Sathiamoorthy, Peng-Chieh Chen, Psalm Haseley, Yonghong Xiao, Semin Lee, J. Seidman, L. Chin, P. Park, R. Kucherlapati, J. Auman, K. Hoadley, Ying Du, M. Wilkerson, Yan Shi, C. Liquori, S. Meng, Ling Li, Yidi Turman, M. Topal, Donghui Tan, S. Waring, Elizabeth Buda, Jesse Walsh, Corbin Jones, P. Mieczkowski, Darshan Singh, Junyuan Wu, Anisha Gulabani, Peter Dolina, T. Bodenheimer, A. Hoyle, J. Simons, Matthew Soloway, Lisle Mose, S. Jefferys, S. Balu, Brian O’Connor, J. Prins, Derek Chiang, D. Hayes, C. Perou, T. Hinoue, D. Weisenberger, D. Maglinte, F. Pan, B. Berman, D. Berg, Hui Shen, T. Triche, S. Baylin, P. Laird, G. Getz, M. Noble, Doug Voat, N. Gehlenborg, D. Dicara, Juinhua Zhang, Hailei Zhang, Chang-Jiun Wu, Spring Liu, S. Shukla, Lihua Zhou, Pei Lin, R. Park, Marc-Danie Nazaire, James Robinson, H. Thorvaldsdóttir, J. Mesirov, V. Thorsson, Sheila Reynolds, Brady Bernard, R. Kreisberg, Jake Lin, L. Iype, Ryan Bressler, Timo Erkkilä, M. Gundapuneni, Yuexin Liu, Adam Norberg, Thomas Robinson, Da Yang, Wei Zhang, I. Shmulevich, J. Ronde, N. Schultz, E. Cerami, G. Ciriello, A. Goldberg, Benjamin Gross, A. Jacobsen, Jianjiong Gao, B. Kaczkowski, Rileen Sinha, B. Aksoy, Yevgeniy Antipin, B. Reva, R. Shen, B. Taylor, M. Ladanyi, C. Sander, R. Akbani, Nianxiang Zhang, B. Broom, Tod Casasent, A. Unruh, Chris Wakefield, S. Hamilton, R. Cason, K. Baggerly, J. Weinstein, D. Haussler, C. Benz, Joshua Stuart, S. Benz, J. Sanborn, Charles Vaske, Jingchun Zhu, C. Szeto, G. Scott, C. Yau, S. Ng, Theodore Goldstein, K. Ellrott, E. Collisson, A. Cozen, D. Zerbino, C. Wilks, Brian Craft, P. Spellman, R. Penny, T. Shelton, M. Hatfield, S. Morris, P. Yena, C. Shelton, M. Sherman, J. Paulauskis, J. Gastier-Foster, Jay Bowen, N. Ramirez, Aaron Black, R. Pyatt, L. Wise, P. White, M. Bertagnolli, Jennifer Brown, T. Chan, Gerald Chu, Christine Czerwinski, F. Denstman, R. Dhir, A. Dörner, C. Fuchs, J. Guillem, M. Iacocca, H. Juhl, Andrew Kaufman, B. Kohl, X. Le, M. Mariano, Elizabeth Medina, M. Meyers, G. Nash, P. Paty, N. Petrelli, B. Rabeno, W. Richards, D. Solit, P. Swanson, L. Temple, J. Tepper, Richard Thorp, E. Vakiani, M. Weiser, J. Willis, G. Witkin, Z. Zeng, M. Zinner, C. Zornig, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Zhining Wang, E. Snyder, J. Pontius, T. Pihl, Brenda Ayala, M. Backus, Jessica Walton, J. Whitmore, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, J. Greene, D. Pot, K. Shaw, Laura Dillon, K. Buetow, Tanja Davidsen, John Demchok, G. Eley, M. Ferguson, P. Fielding, C. Schaefer, Margi Sheth, Liming Yang, M. Guyer, B. Ozenberger, Jacqueline Palchik, Jane Peterson, H. Sofia, E. Thomson (2012)

    Comprehensive molecular characterization of human colon and rectal cancer

    Nature, 487

  • A. Venook, D. Niedzwiecki, F. Innocenti, B. Fruth, C. Greene, B. O'Neil, J. Shaw, J. Atkins, L. Horvath, B. Polite, J. Meyerhardt, E. O’Reilly, R. Goldberg, H. Hochster, C. Blanke, R. Schilsky, R. Mayer, M. Bertagnolli, H. Lenz (2016)

    Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

    Journal of Clinical Oncology, 34

  • M. O’connell, M. Campbell, R. Goldberg, A. Grothey, J. Seitz, J. Benedetti, T. André, D. Haller, D. Sargent (2008)

    Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.1905
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorial 5. Hahnen E, Lederer B, Hauke J, et al. Germline 9. Sikov WM, Berry DA, Perou CM, et al. Event-free early-stage breast cancer: a multicentric analysis of mutation status, pathological complete response, and overall survival following neoadjuvant weekly rates of pathologic complete response and survival. and disease-free survival in triple-negative breast paclitaxel and dose-dense AC +/− carboplatin J Chemother. 2016;28(3):210-217. cancer: secondary analysis of the GeparSixto and/or bevacizumab in triple-negative breast 14. Sharma P, López-Tarruella S, García-Saenz JA, randomized clinical trial [published online July 13, cancer: outcomes from CALGB 40603 (Alliance). et al. Efficacy of neoadjuvant carboplatin plus 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.1007 Paper presented at: San Antonio Breast Cancer docetaxel in triple-negative breast cancer: Symposium; December 9, 2015, San Antonio, TX. 6. von Minckwitz G, Schneeweiss A, Loibl S, et al. combined analysis of two cohorts. Clin Cancer Res. Neoadjuvant carboplatin in patients with 10. Arun B, Bayraktar S, Liu DD, et al. Response to 2017;23(3):649-657. triple-negative and HER2-positive early breast neoadjuvant systemic therapy for breast cancer in 15. Gluz O, Nitz U, Liedtke C, et al. Comparison of cancer (GeparSixto; GBG 66): a randomised phase 2 BRCA mutation carriers and noncarriers: 12 weeks neoadjuvant nab-paclitaxel combined

Journal

JAMA Oncology – American Medical Association

Published: Oct 8, 2017

There are no references for this article.